drugset / Trial / NCT00421213
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
Timeline
- Start
- 2006-12
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darinaparsin | Small molecule | 300 mg/m2 | — |